COVID-19与H1N1所致ARDS住院患者的比较
该回顾性病例对照研究比较了COVID-19(n=73)与H1N1(n=75)所致ARDS患者的临床表现、影像、治疗与预后。COVID-19患者年龄更高、PaO2/FiO2更高(198.5 vs 107.0 mm Hg,P<.001)、磨玻璃影更常见,SOFA评分更低;H1N1患者调整SOFA后死亡率显著更高(率比2.009,95%CI 1.563-2.583,P<.001)。
要点
- COVID-19相关ARDS患者入院时病情严重度评分低于H1N1相关ARDS患者。
- H1N1患者PaO2/FiO2更低、SOFA评分更高,提示氧合与器官功能障碍更重。
- 调整SOFA后H1N1死亡率显著高于COVID-19(率比2.009)。
核心结论
- COVID-19与H1N1所致ARDS在临床表现上存在诸多差异。
- COVID-19患者入院时疾病严重度评分较低,且调整SOFA后死亡率低于H1N1患者。
研究设计与样本
- 回顾性病例对照研究,比较COVID-19(n=73)与H1N1(n=75)两个独立ARDS患者队列。
- 分析并比较两组临床表现、影像学特征、治疗与预后。
主要发现
- COVID-19患者中位年龄高于H1N1患者,H1N1队列男性比例更高(P<.05)。
- COVID-19患者干咳、乏力及胃肠道症状比例高于H1N1患者(P<.05)。
- H1N1患者SOFA评分高于COVID-19患者(P<.05)。
- COVID-19队列PaO2/FiO2为198.5 mm Hg,显著高于H1N1队列的107.0 mm Hg(P<.001)。
- 磨玻璃影在COVID-19患者中比H1N1患者更常见(P<.001)。
关键数值与推荐
- COVID-19住院死亡率28.8%,H1N1住院死亡率34.7%(P=.483)。
- 调整SOFA评分后H1N1患者死亡率显著高于COVID-19患者,率比2.009(95%CI 1.563-2.583;P<.001)。
- COVID-19患者接受抗病毒治疗种类多于H1N1患者。
临床怎么用
- 临床鉴别COVID-19与H1N1相关ARDS时需结合症状谱、氧合指数及影像特征。
- H1N1相关ARDS患者SOFA评分更高、氧合更差,应警惕更重的器官功能障碍。
- 评估ARDS预后时需考虑病因差异及SOFA评分的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since the outbreak of coronavirus disease 2019 (COVID-19) in China in December 2019, considerable attention has been focused on its elucidation. However, it is also important for clinicians and epidemiologists to differentiate COVID-19 from other respiratory infectious diseases such as influenza viruses. RESEARCH QUESTION: The aim of this study was to explore the different clinical presentations between COVID-19 and influenza A (H1N1) pneumonia in patients with ARDS. STUDY DESIGN AND METHODS: This analysis was a retrospective case-control study. Two independent cohorts of patients with ARDS infected with either COVID-19 (n = 73) or H1N1 (n = 75) were compared. Their clinical manifestations, imaging characteristics, treatments, and prognosis were analyzed and compared. RESULTS: The median age of patients with COVID-19 was higher than that of patients with H1N1, and there was a higher proportion of male subjects among the H1N1 cohort (P < .05). Patients with COVID-19 exhibited higher proportions of nonproductive coughs, fatigue, and GI symptoms than those of patients with H1N1 (P < .05). Patients with H1N1 had higher Sequential Organ Failure Assessment (SOFA) scores than patients with COVID-19 (P < .05). The Pao2/Fio2 of 198.5 mm Hg in the COVID-19 cohort was significantly higher than the Pao2/Fio2 of 107.0 mm Hg in the H1N1 cohort (P < .001). Ground-glass opacities was more common in patients with COVID-19 than in patients with H1N1 (P < .001). There was a greater variety of antiviral therapies administered to COVID-19 patients than to H1N1 patients. The in-hospital mortality of patients with COVID-19 was 28.8%, whereas that of patients with H1N1 was 34.7% (P = .483). SOFA score-adjusted mortality of H1N1 patients was significantly higher than that of COVID-19 patients, with a rate ratio of 2.009 (95% CI, 1.563-2.583; P < .001). INTERPRETATION: There were many differences in clinical presentations between patients with ARDS infected with either COVID-19 or H1N1. Compared with H1N1 patients, patients with COVID-19-induced ARDS had lower severity of illness scores at presentation and lower SOFA score-adjusted mortality.
引用
- Tang X, Du RH, Wang R, et al. Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1. Chest. 2020. PMID: 32224074. doi:10.1016/j.chest.2020.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。